A. Åsberg, A. Humar, H. Rollag, A. G. Jardine, H. Mouas, M. D. Pescovitz, D. Sgarabotto, M. Tuncer, I. L. Noronha, A. Hartmann and on behalf of the VICTOR Study Group Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients American Journal of Transplantation 7
Version of Record online: 9 AUG 2007 | DOI: 10.1111/j.1600-6143.2007.01910.x
Oral valganciclovir is an effective and safe treatment option for CMV disease in solid organ transplant recipients. See also editorial by Avery in this issue on page 2062.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field